Table 1b.
Population characteristics for pre-emptive treatment.
| Variable | Population (N= 78) |
|---|---|
|
| |
| Median follow-up, months, (range) | 12 (2–49) |
|
| |
| Patient median age (range) | 47 (0–69) |
|
| |
| Disease, n (%) | |
| AL | 64 (82%) |
| Lymphoma or MM | 6 (8%) |
| MPN | 6 (8%) |
| Other | 2 (2%) |
|
| |
| Disease status, n (%) | |
|
| |
| CR1 | 37 (47%) |
| CR>1 | 23 (30%) |
| Advanced | 18 (23%) |
|
| |
| Donor, n (%) | |
|
| |
| MRD | 12 (15%) |
| MUD | 36 (46%) |
| Haploidentical | 30 (39%) |
|
| |
| Recipient CMV status, n (%) | |
|
| |
| Positive | 74 (95%) |
| Negative | 4 (5%) |
|
| |
| Donor CMV status, n (%) | |
|
| |
| Positive | 43 (55%) |
| Negative | 34 (44%) |
| Unknown | 1 (1%) |
|
| |
| Recipient/donor CMV status, n (%) | |
|
| |
| Neg/neg | 3 (4%) |
| Neg/pos | 1 (1%) |
| Pos/neg | 31 (41%) |
| Pos/pos | 42 (54%) |
|
| |
| Conditioning intensity, n (%) | |
|
| |
| RIC | 22 (28%) |
| MAC | 56 (72%) |
|
| |
| Stem cell source, n (%) | |
|
| |
| PB | 49 (63%) |
| BM | 29 (37%) |
|
| |
| Main GvHD-prophylaxis platform, n (%) | |
|
| |
| T-repleted, ATG-based | 50 (64%) |
| T-repleted, PTCy-based | 13 (17%) |
| T-repleted, other | 9 (11%) |
| Ex-vivo T cell depletion | 6 (8%) |
|
| |
| Details in T-repleted: | |
|
| |
| ATG – CSA+MTX±MMF | 50 |
| ATG alone | 3 |
| PTCy – CSA+MMF | 13 |
| CSA+MTX±MMF | 3 |
| Siroli-MMF | 3 |
|
| |
| ATG dose, median (range) | |
|
| |
| Thymoglobuline (n= 35) | 6 mg/Kg (6–7.5) |
| Fresenius (n= 18) | 20 mg/Kg (20–30) |
Table legend: AL=acute leukemia; MM=Multiple Myeloma; CR=complete remission; MUD=Matched Unrelated Donor; CBU=Cord Blood Unit; MRD=Matched Related Donor; MAC=myeloablative Conditioning; RIC=Reduced Intensity Conditioning; BM=bone marrow; PBSC=Peripheral Blood Stem Cells; CSA=Cyclosporine; MTX=Methotrexate; ATG=Anti-tymocyte Ig; PTCy=Post-Trasplant Ciclophosphamide; MMF=Micophenolate; Siro=Sirolimus.